Biology Department, Payam Noor University, 19395-4697 Tehran, Islamic Republic of Iran.
Department of Chemistry, University of Cambridge, Cambridge, United Kingdom; Section of Biochemical Sciences, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Eur J Med Chem. 2016 Nov 29;124:361-371. doi: 10.1016/j.ejmech.2016.08.056. Epub 2016 Aug 26.
Amyloid or similar protein aggregates are the hallmarks of many disorders, including Alzheimer's, Parkinson's, Huntington's diseases and amyloidoses. The inhibition of the formation of these aberrant species by small molecules is a promising strategy for disease treatment. However, at present, all such diseases lack an appropriate therapeutic approach based on small molecules. In this work we have evaluated five bis(indolyl)phenylmethane derivatives to reduce amyloid fibril formation by hen egg white lysozyme (HEWL) and its associated cytotoxicity. HEWL is a widely used model system to study the fundamentals of amyloid fibril formation and is heterologous to human lysozyme, which forms amyloid fibrils in a familial form of systemic amyloidosis. HEWL aggregation was tested in the presence and absence of the five compounds, under conditions in which the protein is partially unfolded. To this purpose, various techniques were used, including Congo red and Thioflavin T binding assays, atomic force microscopy, Fourier-Transform Infrared spectroscopy and cell-based cytotoxicity assays, such as the MTT reduction test and the trypan blue test. It was found that all compounds inhibited the formation of amyloid fibrils and their associated toxicity, diverging the aggregation process towards the formation of large, morphologically amorphous, unstructured, nontoxic aggregates, thus resembling class I molecules defined previously. In addition, the five compounds also appeared to disaggregate pre-formed fibrils of HEWL, which categorizes them into class IA. The half maximal inhibitory concentration (IC50) was found to be ca 12.3 ± 1.0 μM for the forefather compound.
淀粉样蛋白或类似的蛋白质聚集物是许多疾病的特征,包括阿尔茨海默病、帕金森病、亨廷顿病和淀粉样变性病。通过小分子抑制这些异常物种的形成是一种有前途的疾病治疗策略。然而,目前,所有这些疾病都缺乏基于小分子的适当治疗方法。在这项工作中,我们评估了五个双(吲哚基)苯甲烷衍生物,以减少鸡卵清溶菌酶(HEWL)及其相关细胞毒性的淀粉样纤维形成。HEWL 是研究淀粉样纤维形成基本原理的广泛使用的模型系统,并且与人溶菌酶异源,人溶菌酶在家族性系统性淀粉样变性中形成淀粉样纤维。在存在和不存在这五种化合物的情况下,在蛋白质部分展开的条件下,测试了 HEWL 的聚集。为此,使用了各种技术,包括刚果红和硫黄素 T 结合测定、原子力显微镜、傅里叶变换红外光谱和基于细胞的细胞毒性测定,如 MTT 还原试验和台盼蓝试验。结果发现,所有化合物均抑制了淀粉样纤维的形成及其相关毒性,使聚集过程向形成大的、形态上无定形的、无结构的、无毒的聚集物方向发展,因此类似于先前定义的 I 类分子。此外,这五种化合物似乎还可以解聚 HEWL 的预形成纤维,这将它们归类为 IA 类。前体化合物的半最大抑制浓度(IC50)约为 12.3±1.0 μM。